256 related articles for article (PubMed ID: 36895431)
1. The potential of ketamine for posttraumatic stress disorder: a review of clinical evidence.
Ragnhildstveit A; Roscoe J; Bass LC; Averill CL; Abdallah CG; Averill LA
Ther Adv Psychopharmacol; 2023; 13():20451253231154125. PubMed ID: 36895431
[TBL] [Abstract][Full Text] [Related]
2. The safety and efficacy of ketamine NMDA receptor blocker as a therapeutic intervention for PTSD review of a randomized clinical trial.
Jumaili WA; Trivedi C; Chao T; Kubosumi A; Jain S
Behav Brain Res; 2022 Apr; 424():113804. PubMed ID: 35181391
[TBL] [Abstract][Full Text] [Related]
3. The emergence of ketamine as a novel treatment for posttraumatic stress disorder.
Feder A; Rutter SB; Schiller D; Charney DS
Adv Pharmacol; 2020; 89():261-286. PubMed ID: 32616209
[TBL] [Abstract][Full Text] [Related]
4. Ketamine as a Novel Psychopharmacotherapy for Eating Disorders: Evidence and Future Directions.
Ragnhildstveit A; Slayton M; Jackson LK; Brendle M; Ahuja S; Holle W; Moore C; Sollars K; Seli P; Robison R
Brain Sci; 2022 Mar; 12(3):. PubMed ID: 35326338
[TBL] [Abstract][Full Text] [Related]
5. Efficacy, Safety, and Durability of Repeated Ketamine Infusions for Comorbid Posttraumatic Stress Disorder and Treatment-Resistant Depression.
Albott CS; Lim KO; Forbes MK; Erbes C; Tye SJ; Grabowski JG; Thuras P; Batres-Y-Carr TM; Wels J; Shiroma PR
J Clin Psychiatry; 2018; 79(3):. PubMed ID: 29727073
[TBL] [Abstract][Full Text] [Related]
6. Pharmacotherapy for posttraumatic stress disorder.
Stein DJ; Zungu-Dirwayi N; van Der Linden GJ ; Seedat S
Cochrane Database Syst Rev; 2000; (4):CD002795. PubMed ID: 11034765
[TBL] [Abstract][Full Text] [Related]
7. A Randomized Controlled Trial of Repeated Ketamine Administration for Chronic Posttraumatic Stress Disorder.
Feder A; Costi S; Rutter SB; Collins AB; Govindarajulu U; Jha MK; Horn SR; Kautz M; Corniquel M; Collins KA; Bevilacqua L; Glasgow AM; Brallier J; Pietrzak RH; Murrough JW; Charney DS
Am J Psychiatry; 2021 Feb; 178(2):193-202. PubMed ID: 33397139
[TBL] [Abstract][Full Text] [Related]
8. Ketamine for treatment of mood disorders and suicidality: A narrative review of recent progress.
Kritzer MD; Mischel NA; Young JR; Lai CS; Masand PS; Szabo ST; Mathew SJ
Ann Clin Psychiatry; 2022 Feb; 34(1):33-43. PubMed ID: 35166663
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of intravenous ketamine for treatment of chronic posttraumatic stress disorder: a randomized clinical trial.
Feder A; Parides MK; Murrough JW; Perez AM; Morgan JE; Saxena S; Kirkwood K; Aan Het Rot M; Lapidus KA; Wan LB; Iosifescu D; Charney DS
JAMA Psychiatry; 2014 Jun; 71(6):681-8. PubMed ID: 24740528
[TBL] [Abstract][Full Text] [Related]
10. A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action.
Naughton M; Clarke G; O'Leary OF; Cryan JF; Dinan TG
J Affect Disord; 2014 Mar; 156():24-35. PubMed ID: 24388038
[TBL] [Abstract][Full Text] [Related]
11. [Posttraumatic stress disorder (PTSD) as a consequence of the interaction between an individual genetic susceptibility, a traumatogenic event and a social context].
Auxéméry Y
Encephale; 2012 Oct; 38(5):373-80. PubMed ID: 23062450
[TBL] [Abstract][Full Text] [Related]
12. The Safety, Clinical, and Neurophysiological Effects of Intranasal Ketamine in Patients Who Do Not Respond to Electroconvulsive Therapy: Protocol for a Pilot, Open-Label Clinical Trial.
Knyahnytska Y; Zomorrodi R; Kaster T; Voineskos D; Trevizol A; Blumberger D
JMIR Res Protoc; 2022 Jan; 11(1):e30163. PubMed ID: 34882570
[TBL] [Abstract][Full Text] [Related]
13. Arketamine, a new rapid-acting antidepressant: A historical review and future directions.
Zhang JC; Yao W; Hashimoto K
Neuropharmacology; 2022 Nov; 218():109219. PubMed ID: 35977629
[TBL] [Abstract][Full Text] [Related]
14. The Neurobiology and Pharmacotherapy of Posttraumatic Stress Disorder.
Abdallah CG; Averill LA; Akiki TJ; Raza M; Averill CL; Gomaa H; Adikey A; Krystal JH
Annu Rev Pharmacol Toxicol; 2019 Jan; 59():171-189. PubMed ID: 30216745
[TBL] [Abstract][Full Text] [Related]
15. Rapid-acting antidepressant ketamine, its metabolites and other candidates: A historical overview and future perspective.
Hashimoto K
Psychiatry Clin Neurosci; 2019 Oct; 73(10):613-627. PubMed ID: 31215725
[TBL] [Abstract][Full Text] [Related]
16. Ketamine for Treatment of Posttraumatic Stress Disorder: State of the Field.
Fremont R; Brown O; Feder A; Murrough J
Focus (Am Psychiatr Publ); 2023 Jul; 21(3):257-265. PubMed ID: 37404968
[TBL] [Abstract][Full Text] [Related]
17. Neurocognitive effects of repeated ketamine infusions in comorbid posttraumatic stress disorder and major depressive disorder.
Albott CS; Lim KO; Erbes C; Thuras P; Wels J; Tye SJ; Shiroma PR
J Affect Disord; 2022 Jul; 308():289-297. PubMed ID: 35429529
[TBL] [Abstract][Full Text] [Related]
18. Relapse prevention in treatment-resistant major depressive disorder with rapid-acting antidepressants.
Singh JB; Fedgchin M; Daly EJ; Drevets WC
Adv Pharmacol; 2020; 89():237-259. PubMed ID: 32616208
[TBL] [Abstract][Full Text] [Related]
19. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate CA; Singh JB; Carlson PJ; Brutsche NE; Ameli R; Luckenbaugh DA; Charney DS; Manji HK
Arch Gen Psychiatry; 2006 Aug; 63(8):856-64. PubMed ID: 16894061
[TBL] [Abstract][Full Text] [Related]
20. Ketamine for Treatment-Resistant Depression: a New Advocate.
Pérez-Esparza R
Rev Invest Clin; 2018; 70(2):65-7. PubMed ID: 29718013
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
